Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Niagen Bioscience (NAGE) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • Niagen Bioscience's Change in Accured Expenses rose 3583.93% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 39874.69%. This contributed to the annual value of $1.2 million for FY2024, which is 4406.31% down from last year.
  • Latest data reveals that Niagen Bioscience reported Change in Accured Expenses of $1.3 million as of Q3 2025, which was up 3583.93% from -$1.7 million recorded in Q2 2025.
  • Niagen Bioscience's Change in Accured Expenses' 5-year high stood at $1.6 million during Q1 2022, with a 5-year trough of -$1.8 million in Q2 2024.
  • Its 5-year average for Change in Accured Expenses is $286789.5, with a median of $762000.0 in 2021.
  • Per our database at Business Quant, Niagen Bioscience's Change in Accured Expenses plummeted by 5856666.67% in 2021 and then surged by 175666.67% in 2023.
  • Quarter analysis of 5 years shows Niagen Bioscience's Change in Accured Expenses stood at $150000.0 in 2021, then skyrocketed by 287.33% to $581000.0 in 2022, then tumbled by 48.36% to $300000.0 in 2023, then skyrocketed by 269.0% to $1.1 million in 2024, then increased by 19.15% to $1.3 million in 2025.
  • Its Change in Accured Expenses was $1.3 million in Q3 2025, compared to -$1.7 million in Q2 2025 and $1.2 million in Q1 2025.